Executive Intelligence

Thomas Clozel

Founder

Thomas Clozel is listed as a founder of Owkin based in France on Brel Digital’s verified company intelligence record.

Company Intelligence Official Website
In this profile

Quick Facts

  • Role Founder
  • Company Owkin
  • Country France
  • Industry AI in Healthcare
  • Founded 2016
  • Known For Owkin's June 2026 Sanofi K Pro collaboration extends a multi-year pharma alliance into agentic AI agents…
  • Status Active
  • Last Reviewed Jul 2026

Executive Summary

Thomas Clozel appears in Brel Digital’s verified company_founders attribution for Owkin based in France in the Healthcare sector. This profile records that founder relationship using sources already on file for the company. Personal biography details that are not evidenced in those sources are omitted. Company context (from the verified Owkin profile): Paris TechBio company building agentic AI for biopharma discovery through K Pro and federated patient-data networks Why the company matters (verified company field): Owkin's June 2026 Sanofi K Pro collaboration extends a multi-year pharma alliance into agentic AI agents — a signal that large pharmas are licensing vertical AI scientists, not just point analytics dashboards. Official company website on file: https://www.owkin.com. Readers should consult that site and the Sources section for primary evidence. Brel Digital does not invent prior roles, education, funding history, or awards for founder profiles. Where additional verified public leadership pages become available, this profile should be deepened in a subsequent editorial review.

Career Timeline

Verified company milestones linked to this executive’s organization.

  1. 2016 Company founded

    Owkin was founded in 2016 per the company profile source on file.

    Source
  2. 2016 Development

    2016: Owkin co-founded in Paris by Thomas Clozel, MD, and Gilles Wainrib, PhD.

    Source
  3. 2026 Development

    June 5, 2026: Owkin announced multi-year Sanofi collaboration to co-develop biopharma AI agents backed by a five-year K Pro license.

    Source
  4. 2026 Development

    May 13, 2026: Owkin announced multi-year K Pro license agreement with AstraZeneca.

    Source

Connected Company

Connected Products

Biotechnology

Owkin — Biotechnology

K Pro agentic AI platform and federated learning infrastructure connecting multimodal patient data with biological reasoning…

View Product

Connected Reports

Connected Insights

Industry Intelligence

AI in Healthcare Open industry

Thomas Clozel appears in Brel Digital’s verified company_founders attribution for Owkin based in France in the Healthcare sector. This profile records that founder relationship using sources already on file for the company. Personal biography details that are not evidenced in those sources are omitted.

Company context (from the verified Owkin profile): Paris TechBio company building agentic AI for biopharma discovery through K Pro and federated patient-data networks

Why the company matters (verified company field): Owkin's June 2026 Sanofi K Pro collaboration extends a multi-year pharma alliance into agentic AI agents — a signal that large pharmas are licensing vertical AI scientists, not just point analytics dashboards.

Official company website on file: https://www.owkin.com. Readers should consult that site and the Sources section for primary evidence.

Brel Digital does not invent prior roles, education, funding history, or awards for founder profiles. Where additional verified public leadership pages become available, this profile should be deepened in a subsequent editorial review.

Sources and references

This article draws on publicly available company information, official websites, filings, interviews, announcements, and other cited sources. Information may change over time.

Request a correction if you represent this company or believe information is inaccurate.

The AI Brief

Founder and company intelligence, weekly.

Subscribe